Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Nordic Mines in connection with new share issues
Mandate

Vinge advises Nordic Mines in connection with new share issues

January 04, 2010

Vinge has advised Nordic Mines AB (publ) in connection with a directed share issue of SEK 180 million and a preferential rights issue of approximately SEK 60 million. The issues, which total approximately SEK 240 million, are intended to allow Nordic Mines to secure the equity required to carry out an investment in the company's planned gold mine located in Laiva in Finland.

The issue resolutions are conditional upon approval by the shareholders at the extraordinary shareholders' meeting to be held on 11 January 2010.

Vinge's team consisted of responsible partner Göran Nyström and associates Jesper Schönbeck, Emil Hedberg and Andreas Wirén.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024